Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.53 |
| ▸ | KIF11 | P52732 | 12/20 | 0.48 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514712 | 1.00 | CYP11B2 (0.53) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL15744302 | 0.86 | DGAT1 (0.41) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL18285726 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL5361521 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL29988758 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL415598 | 0.82 | CYP11B1 (0.39) | CYP11B2CYP11B1KIF11KDM1ADGAT1 | |
| SCHEMBL690073 | 0.81 | PTPN7 (0.47) | CYP11B2CYP11B1KDM1ADGAT1 | |
| SCHEMBL29890371 | 0.81 | PTPN7 (0.47) | CYP11B2CYP11B1KDM1ADGAT1 | |
| SCHEMBL6267032 | 0.80 | KDM1A (0.50) | CYP11B2CYP11B1KDM1A | |
| SCHEMBL30864218 | 0.80 | KDM1A (0.50) | CYP11B2CYP11B1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110885290-A | Synthetic method of 3-fluoro-2-methyl-4-trifluoromethylaniline hydrochloride | 阿里生物新材料（常州）有限公司 | 2020-03-17 | — | — | CN | claimed |
| CN-102633595-A | Fluorine-containing tetracyclic liquid crystal compound, and synthesis method and application thereof | Shanghai tianwen chemical co ltd | 2012-08-15 | — | — | CN | claimed |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20260022100-A1 | NAV1.8 INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2026-01-22 | — | — | US | disclosed |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| EP-4634161-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| EP-4611743-A1 | TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | Merck Sharp & Dohme LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-6432863-B2 | FOR TRANSITION METAL CATALYST | W. R. GRACE & CO.-CONN. | 2002-08-13 | — | — | US | disclosed |
| US-20020006863-A1 | HALOGENATED SUPPORTS AND SUPPORTED ACTIVATORS | W.R. GRACE & CO.-CONN. | 2002-01-17 | — | — | US | disclosed |
| US-20010018395-A1 | HALOGENATED SUPPORTS AND SUPPORTED ACTIVATORS | W.R. GRACE & CO.-CONN. | 2001-08-30 | — | — | US | disclosed |
| EP-0830385-B1 | HALOGENATED SUPPORTS AND SUPPORTED ACTIVATORS | GRACE W R & CO (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5885924-A | REACTING A CARRIER CONTAINING REACTIVE FUNCTIONALITIES, E.G., HYDROXYL CONTAINING SILICA, WITH HALOGENATED ORGANIC COMPOUNDS, E.G., FLUOROSUBSTITUTED PHENOLS, IN THE PRESENCE OF A BASE | W. R. GRACE & CO.-CONN. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5858272-A | HAVING A LARGE .DELTA..EPSILON. WHILE MAINTAINING A HIGH VOLTAGE HOLDING RATIO; DRIVING THIN FILM TRANSISTOR AT LOW VOLTAGE; EXCELLANT COMPATIBILITY WITH CONVENTIONAL LIQUID CRYSALS; RELIABILITY | CHISSO CORPORATION (JP) | 1999-01-12 | — | — | US | disclosed |
| CN-1182085-A | Phenyldioxane derivatives, liquid crystal compositions, and liquid crystal display elements | CHISSO CORP (JP) | 1998-05-20 | — | — | CN | disclosed |
| EP-0819685-A1 | Phenyldioxane derivatives, liquid crystal compositions, and liquid crystal display elements | Chisso Corporation (JP) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996040796-A1 | HALOGENATED SUPPORTS AND SUPPORTED ACTIVATORS | W.R. GRACE & CO.-CONN. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | CYP11B2 1206/4885CYP11B1 2281/4885KIF11 4443/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | CYP11B2 3027/4885CYP11B1 2713/4885KIF11 2890/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | CYP11B2 2623/4885CYP11B1 2100/4885KIF11 2932/4885 |
| US-20260022100-A1 | NAV1.8 INHIBITOR | SCN8A, SCN1B, SCN1A | CYP11B2 675/4885CYP11B1 484/4885KIF11 1449/4885 |
| US-20260034113-A1 | THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, NR3C2, SRD5A1 | CYP11B2 7/4885CYP11B1 8/4885KIF11 3246/4885 |
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | CYP11B2 158/4885CYP11B1 255/4885KIF11 2575/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | CYP11B2 694/4885CYP11B1 672/4885KIF11 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.